ShiraTronics develops a Migraine Therapy System that delivers neurostimulation intended to reduce headache days and attack severity and improve quality of life for chronic migraine patients. The company reported encouraging reductions in headache days, decreased migraine severity, and improved quality-of-life scores in its first-in-human pilot study. ShiraTronics received Breakthrough Device designation from the FDA's CDRH in 2021. It is now running an FDA-approved pivotal trial (RELIEV-CM2), a multi-center, blinded, randomized, sham-controlled study targeting patients who have failed current medical therapies. The company plans to use new funding to support that pivotal trial, pursue FDA premarket approval, and fund the initial commercial launch of its therapy. Rob Binney serves as CEO and is leading the company through these regulatory and commercialization milestones. ShiraTronics is a Brooklyn Park, Minnesota-based private medical device company focused on an innovative therapy for migraine headaches. The company is developing and clinically testing a neuromodulation technology as its core product. ShiraTronics was spun off from NuXcel, an electrical medical device accelerator. The company is led by President and CEO Lynn Elliott and co-founder and Chairman Mudit K. Jain, PhD. It completed an additional $3M Series A, bringing the Series A to $36M, and intends to use the funds to further accelerate its path to market. ShiraTronics is a Minneapolis-based private medical device company developing an innovative neuromodulation approach to treat migraine headaches. The company is focused on developing and clinically testing its neuromodulation technology. ShiraTronics was seeded in 2019 as a spin-off from NuXcel, a medical device accelerator managed by co-founder Mudit K. Jain, PhD, and Lynn Elliott. Lynn Elliott joined as President and CEO, with Mudit K. Jain serving as co-founder and Chairman of the Board. Prior to the Series A the company was backed by Strategic HealthCare Investment Partners (S.H.I.P.). In October 2019 ShiraTronics completed a $33M Series A financing to advance its clinical development.

Total raised

$102M

Funding rounds

3

Latest round

Series B

Latest activity

Oct 2024